



# Alkyl Amines Chemicals Limited

Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA  
Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com



**Responsible Care®**  
OUR COMMITMENT TO SUSTAINABILITY

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Rs.in Lakhs  
(Except per share data)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		Dec 31, 2020	Sep 30, 2020	Dec 31, 2019	Dec 31, 2020	Dec 31, 2019	Mar 31, 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	32,388.57	29,126.83	25,691.11	86,030.62	75,811.24	99,287.76
II.	Other Income	165.98	270.58	216.72	554.62	439.22	701.16
III.	<b>Total Revenue (I+II)</b>	<b>32,554.55</b>	<b>29,397.41</b>	<b>25,907.83</b>	<b>86,585.24</b>	<b>76,250.46</b>	<b>99,988.92</b>
IV.	<b>Expenses</b>						
	Cost of Materials Consumed	12,771.33	12,035.98	11,445.87	35,600.75	36,567.32	47,621.68
	Changes in Inventories of Finished Goods and Work-in-Progress	(102.10)	356.00	16.02	273.71	1,091.94	827.78
	Employee benefit costs	2,398.28	2,130.24	1,903.79	6,520.20	5,268.41	6,964.15
	Finance Costs	137.06	161.85	213.45	491.27	836.07	1,025.39
	Depreciation and Amortisation Expense	756.54	721.29	680.26	2,179.79	1,970.74	2,690.98
	Other Expenses	5,012.05	5,078.42	5,067.97	14,062.61	13,939.84	18,172.17
	<b>Total Expenses (IV)</b>	<b>20,973.16</b>	<b>20,483.78</b>	<b>19,327.36</b>	<b>59,128.33</b>	<b>59,674.32</b>	<b>77,302.15</b>
V.	<b>Profit before Exceptional Items and Tax (III-IV)</b>	<b>11,581.39</b>	<b>8,913.63</b>	<b>6,580.47</b>	<b>27,456.91</b>	<b>16,576.14</b>	<b>22,686.77</b>
VI.	<b>Exceptional Items</b>	-	-	3,284.16	-	3,284.16	3,284.16
VII.	<b>Profit before tax (V+VI)</b>	<b>11,581.39</b>	<b>8,913.63</b>	<b>9,864.63</b>	<b>27,456.91</b>	<b>19,860.30</b>	<b>25,970.93</b>
VIII.	<b>Tax Expense :</b>						
	Current Tax	3,133.12	2,182.39	1,694.50	6,861.47	3,950.42	5,403.55
	Deferred Tax	(340.77)	184.04	491.88	(11.40)	(763.30)	(1,030.04)
	Tax adjustments of earlier years	340.13	-	(30.40)	332.60	65.87	69.30
	<b>Total Tax Expenses</b>	<b>3,132.48</b>	<b>2,366.43</b>	<b>2,155.98</b>	<b>7,182.67</b>	<b>3,252.99</b>	<b>4,442.81</b>
IX.	<b>Net Profit for the period/year (VII-VIII)</b>	<b>8,448.91</b>	<b>6,547.20</b>	<b>7,708.65</b>	<b>20,274.24</b>	<b>16,607.31</b>	<b>21,528.12</b>
X.	<b>Other Comprehensive Income/ (Expense)</b>						
	a) Items that will not be reclassified to profit or loss						
	- Remeasurement gain/(losses) on defined benefit plans	(136.33)	(22.02)	(49.65)	(237.84)	(158.04)	(171.17)
	b) Income tax relating to items that will not be reclassified to profit or loss	35.22	6.10	11.45	58.91	38.55	40.38
	c) Items that may be reclassified to profit or loss						
	- Deferred gains/(losses) on cash flow hedges reserves	(5.73)	(154.66)	(64.69)	(106.86)	(0.06)	0.80
	d) Income tax relating to items that may be reclassified to profit or loss	1.02	37.29	14.60	26.48	0.01	(0.18)
	<b>Other Comprehensive Income / (Expense) for the period/year (Net of Tax)</b>	<b>(105.82)</b>	<b>(133.29)</b>	<b>(88.29)</b>	<b>(259.31)</b>	<b>(119.54)</b>	<b>(130.17)</b>
XI.	<b>Total Comprehensive Income for the period/year (IX+X)</b>	<b>8,343.09</b>	<b>6,413.91</b>	<b>7,620.36</b>	<b>20,014.93</b>	<b>16,487.77</b>	<b>21,397.95</b>
XII.	<b>Paid up Share Capital</b>	<b>1,020.64</b>	<b>1,020.50</b>	<b>1,019.82</b>	<b>1,020.64</b>	<b>1,019.82</b>	<b>1,019.82</b>
XIII.	<b>Face Value of Share (Rs)</b>	<b>5.00</b>	<b>5.00</b>	<b>5.00</b>	<b>5.00</b>	<b>5.00</b>	<b>5.00</b>
XIV.	<b>Earnings Per Equity Share</b>						
	Basic (Rs)	41.39	32.08	37.79	99.32	81.42	105.55
	Diluted (Rs)	41.29	32.00	37.69	99.07	81.21	105.27



**Notes :**

- 1 The above unaudited financial results have been reviewed and recommended by the Audit Committee at their meeting held on February 2, 2021, and approved by the Board of Directors at their meeting on the same date. The Limited Review, as required under the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2020 and they have expressed an unmodified opinion on the same.
- 2 The Company is primarily engaged in the business of "Specialty Chemicals". Accordingly, there are no reportable Segments.
- 3 There has not been any adverse impact of COVID-19 on the Company's business operations so far. The Company expects that the demand for its products from the pharmaceutical sector will continue. However, the Company will continue to evaluate the pandemic related uncertainty with respect to its business and economic conditions and update its assessment.
- 4 The Board of Directors have declared an interim dividend at the rate of 200% (i.e. Rs 10/- per share) on 2,04,12,711 Equity Shares of Rs 5/- each fully paid up.
- 5 The Board of Directors have approved, subject to approval of shareholders through postal ballot, the sub-division of Equity Share of face value of Rs 5/- each to Equity Shares of face value of Rs.2/- each.
- 6 The Board of Directors have approved the investments for the enhancement of capacity for Aliphatic Amines at Kurkumbh & Patalganga sites in Maharashtra.
- 7 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

FOR ALKYL AMINES CHEMICALS LTD.

Place : Mumbai  
Date : February 02,2021

YOGESH M.KOTHARI  
CHAIRMAN & MANAGING DIRECTOR

